Aberrant high expression of immunoglobulin G in epithelial stem/progenitor-like cells contributes to tumor initiation and metastasis.
Qinyuan Liao,Wei Liu,Yang Liu,Fulin Wang,Chong Wang,Jingxuan Zhang,Ming Chu,Dongyang Jiang,Lin Xiao,Wenwei Shao,Zhengzuo Sheng,Xia Tao,Lei Huo,C Cameron Yin,Youhui Zhang,Gregory Lee,Jing Huang,Zihai Li,Xiaoyan Qiu
DOI: https://doi.org/10.18632/oncotarget.5542
2015-01-01
Oncotarget
Abstract:High expression of immunoglobulin G (IgG) in many non-B cell malignancies and its non-conventional roles in promoting proliferation and survival of cancer cells have been demonstrated. However, the precise function of non-B IgG remains incompletely understood. Here we define the antigen specificity of RP215, a monoclonal antibody that specifically recognizes the IgG in cancer cells. Using RP215, our study shows that IgG is overexpressed in cancer cells of epithelial lineage, especially cells with cancer stem/progenitor cell-like features. The RP215-recognized IgG is primarily localized on the cell surface, particularly lamellipodia-like structures. Cells with high IgG display higher migration, increased invasiveness and metastasis, and enhanced self-renewal and tumorgenecity ability in vitro and in vivo. Importantly, depletion of IgG in breast cancer leads to reduced adhesion, invasion and self-renewal and increased apoptosis of cancer cells. We conclude that high expression of IgG is a novel biomarker of tumor progression, metastasis and cancer stem cell maintenance and demonstrate the potential therapeutic benefits of RP215-recognized IgG targeted strategy.